Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: Implications for clinical trial design and interpretation

Cancer

Volumn 116, Issue 2, 2010, Pages 347-354

  Patil, Sujata ^a   Ishill, Nicole ^a   Deluca, John ^a   Motzer, Robert J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Memorial sloan kettering cancer center risk groups; Metastatic renal cell carcinoma; Prognostic factors; Stage migration; Trends

Indexed keywords

10 DEAZAAMINOPTERIN; 2,2' ANHYDRO 5 FLUOROCYTOSINE ARABINOSIDE; AGATOLIMOD; ALPHA INTERFERON; ARSENIC TRIOXIDE; BISANTRENE; BORTEZOMIB; CALCIUM; CETUXIMAB; DOXORUBICIN; ELLIPTINIUM; EPIRUBICIN; FLUTAMIDE; HEMOGLOBIN; IDARUBICIN; INTERLEUKIN 12; INTERLEUKIN 2; ISOTRETINOIN; LACTATE DEHYDROGENASE; MITOGUAZONE; N METHYLFORMAMIDE; PEGINTERFERON ALPHA; SURAMIN; TEMSIROLIMUS; THALIDOMIDE; TOPOTECAN; TRIMETREXATE; UNINDEXED DRUG; VINBLASTINE; VINDESINE;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CANCER CENTER; CANCER LOCALIZATION; CANCER PATIENT; CONTROLLED STUDY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 75649113399     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24713     Document Type: Article

References (42)

1. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-2281.
2. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124.
3. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20:289-296.
4. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530-2540.
5. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22:454-463.
6. Motzer RJ, Bacik J, Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience. Clin Cancer Res. 2004;10(18 pt 2):6302S-6303S.
7. Bukowski RM, Negrier S, Elson P. Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group. Clin Cancer Res. 2004;10(18 pt 2):6310S-6314S.
8. Motzer RJ, Bukowski, Figlin RA, et al. Prognostic nomogram for sunitinib in patients with metastatis renal cell carcinoma. Cancer. 2008;113:1552-1558.
9. Wong PP, Yagoda A, Currie VE, et al. Phase II study of vindesine sulfate in the therapy for advanced renal carcinoma. Cancer Treat Rep. 1977;61:1727-1729.
10. Zeffren J, Yagoda A, Watson RC, et al. Phase II trial of methyl-GAG in advanced renal cancer. Cancer Treat Rep. 1981;65:525-527.
11. Ahmed T, Benedetto P, Yagoda A, et al. Estrogen, progesterone, and androgen-binding sites in renal cell carcinoma. Observations obtained in phase II trial of flutamide. Cancer. 1984;54:477-481.
12. Scher HI, Yagoda A, Ahmed T, et al. Phase II trial of 10-deazaaminopterin for advanced hypernephroma. Anticancer Res. 1984;4:409-410.
13. Benedetto P, Ahmed T, Needles B, et al. Phase II trial of 4'epi-adriamycin for advanced hypernephroma. Am J Clin Oncol. 1983;6:553-554.
14. Scher H, Schwartz S, Yagoda A, et al. Phase II trial of bisantrene for advanced hypernephroma. Cancer Treat Rep. 1982;66:1653-1655.
15. Scher HI, Yagoda A, Ahmed T, et al. Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephroma. Cancer Chemother Pharmacol. 1985;14:79-80.
16. Minasian LM, Motzer RJ, Gluck L, et al. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol. 1993;11:1368-1375.
17. Sternberg CN, Yagoda A, Casper E, et al. Phase II trial of elliptinium in advanced renal cell carcinoma and carcinoma of the breast. Anticancer Res. 1985;5:415-417.
18. Sternberg CN, Yagoda A, Scher HI, et al. Phase II trial of N-methylformamide for advanced renal cell carcinoma. Cancer Treat Rep. 1986;70:681-682.
19. Sternberg CN, Yagoda A, Scher H, et al. Phase II trial of trimetrexate in patients with advanced renal cell carcinoma. Clinical Community Oncology Program. Eur J Cancer Clin Oncol. 1989;25:753-754.
20. Murray Law T, Motzer RJ, Mazumdar M, et al. Phase III randomized trial of interleukin-2 with or without lymphineactivated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer. 1995;76:824-832.
21. Motzer RJ, Scher H, Bajorin D, et al. Phase II trial of Didemnin B in patients with advanced renal cell carcinoma. Invest New Drugs. 1990;8:391-392.
22. Ilson D, Motzer RJ, Kradin RL, et al. A phase II study of recombinant interleukin-2 and alpha interferon for patients with advanced renal cell carcinoma. J Clin Oncol. 1992; 10:1124-1130.
23. Motzer RJ, Nanus DM, O'Moore P, et al. Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression. Cancer Res. 1992;52:5775-5779.
24. Motzer RJ, Lyn P, Fischer P, et al. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol. 1995;13:1958-1965.
25. Murray Law T, Ilson DH, Motzer RJ. Phase II trial of topotecan in patients with advanced renal cell carcinoma. Invest New Drugs. 1994;12:143-145.
26. Murray Law T, Mencel P, Motzer RJ. Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma. Invest New Drugs. 1994;12:323-325.
27. Motzer RJ, Schwartz L, Murray Law T, et al. Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol. 1995;13:1950-1957.
28. Berg WJ, Schwartz LH, Amsterdam A, et al. A phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma. Invest New Drugs. 1997;15:353-355.
29. Motzer RJ, Rakhit A, Schwartz LH, et al. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res. 1998;4:1183-1191.
30. Motzer RJ, Rakhit A, Thompson JA, et al. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma. J Interferon Cytokine Res. 2001;21:257-263.
31. Motzer RJ, Amato R, Todd M, et al. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs. 2003;21:99-101.
32. Divgi CR, O'Donoghue JA, Welt S, et al. Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med. 2004;45:1412-1421.
33. Motzer RJ, Rakhit A, Thompson J, et al. Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma. Ann Oncol. 2002;13:1799-1805.
34. Berg WJ, Schwartz L, Yu R, et al. Phase II trial of irofulven (6-hydroxymethaylacylfulvene) for patients with advanced renal cell carcinoma. Invest New Drugs. 2001;19:317-320.
35. Motzer RJ, Berg W, Ginsberg M, et al. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol. 2002;20:302-306.
36. Vuky J, Yu R, Schwartz L, Motzer RJ. Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. Invest New Drugs. 2002;20:327-330.
37. Kondagunta GV, Drucker B, Schwartz L, et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol. 2004;22:3720-3725.
38. Feldman DR, Kondagunta GV, Schwartz L, et al. Phase II trial of pegylated interferon-alpha 2b in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2008;6:25-30.
39. Motzer RJ, Hudes GR, Curti BD, et al. Phase I/II trial of temsirolimus combines with interferon alfa for advances renal cell carcinoma. J Clin Oncol. 2007;24:3958-3964.
40. Slovin SF, Motzer RJ, Jefferson M, et al. Phase I trial of a PSMA DNA vaccine for patients (pts) with good risk renal cell carcinoma (RCC) [abstract]. J Clin Oncol. 2008; 26(suppl). Abstract 16073.
41. Patel PH, Kondagunta GV, Schwartz L, et al. Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma. Invest New Drugs. 2008;26:273-276.
42. Ronnen EA, Kondagunta GV, Ishill N, et al. A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs. 2006;24:543-546.